APS March Meeting 2013 
Volume 58, Number 1
Monday–Friday, March 18–22, 2013;
Baltimore, Maryland
Session J4: Invited Session: Physics Challenges in Biophysics
2:30 PM–5:30 PM, 
Tuesday, March 19, 2013
Room: Ballroom IV
Sponsoring
Unit: 
FIAP
Chair: Cha-Mei Tang, Creatv Micro Tech Inc
Abstract ID: BAPS.2013.MAR.J4.2
Abstract: J4.00002 : Diagnostic Applications and Methods to Isolate Circulating Tumor Cells (CTCs) from Blood
3:06 PM–3:42 PM
Preview Abstract
  
 Abstract
  Abstract   
Author:
Cha-Mei Tang
(Creatv MicroTech, Inc.)
Each year a million new cancer cases are diagnosed in the United States. 
Ninety percent of the deaths will be the result of metastasis, not from the 
primary tumor. Tissue biopsy is a universally accepted tool for cancer 
diagnosis and determination of treatment. The procedure varies, but is 
invasive, costly, and can be fatal, and for these reasons is seldom repeated 
after initial diagnosis. Monitoring of treatment response and for possible 
relapse is usually done by CT or MRI scan, both of which are expensive and 
require the tumor to change size perceptibly. Further, cancer can mutate or 
develop resistance to therapeutics and require modification of the treatment 
regimen. The initial tissue biopsy often cannot reflect the disease as it 
progresses, requiring new biopsy samples to determine a change of treatment.
All carcinomas, about 80{\%} of all cancer, shed tumor cells into the 
circulation, most often at the later stages when treatment is more critical. 
These circulating tumor cells (CTCs) are the cause of metastasis, and can be 
isolated from patient blood to serve as ``liquid biopsy''. These CTCs 
contain a valuable trove of information that help both patient and clinician 
understand disease status. In addition to counting the number of CTCs (known 
to be a prognostic indicator of survival), CTCs can provide biomarker 
information such as protein expressions and gene mutations, amplifications, 
and translocations. This information can be used to determine treatment. 
During treatment, the number of intact and apoptotic CTCs can be measured on 
a repeated basis to measure the patient's response to treatment and disease 
progression. Following treatment, liquid biopsy can be repeated at regular 
intervals to watch for relapse. 
Methods to isolate CTCs can be grouped into three categories: i) 
immunocapture based on surface markers of CTCs, ii) size exclusion based on 
CTC size, typically larger than blood cells, and iii) negative selection 
utilizing red blood cell lysis, white blood cell depletion or FICOLL. 
Various implementations of the CTC isolation methods will be presented.
To cite this abstract, use the following reference: http://meetings.aps.org/link/BAPS.2013.MAR.J4.2